Skip to main content

Table 5 Ongoing clinical trials of immune-checkpoint inhibitors combined with non-cytotoxic agents

From: Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges

Clinical trial ID Phase Setting Regimen Endpoint
NCT03041311 II 1st line CE plus atezolizumab +/− Trilaciclib OS
AEs
NCT02922764 I 2nd line (solid tumors) RGX-104 +/− Nivolumab MTD
ORR
PFS
NCT02712905 I/II ≥ 2nd line (solid tumors) INCB059872 plus Nivolumab (part 3) AEs
NCT03126110 I/II ≥ 2nd line INCAGN01876 plus nivolumab/ipilimumab/nivo+ipi AEs
ORR
NCT03241173 I/II ≥ 2nd line INCAGN01949 plus nivolumab/ipilimumab/nivo+ipi AEs
ORR
NCT03026166 I/II ≥ 2nd line Rova-T plus Nivolumab +/− ipilimumab DLT
NCT03085849 I 2nd line SGI-110 followed by Durvalumab plus Tremelimumab MTD
NCT02734004 (MEDIOLA) I/II 2nd line Durvalumab plus olaparib DCR
ORR
AEs
NCT02554812 Ib/II ≥ 2nd line Avelumab plus utomilumab DLT
OR
  1. PFS Progression Free Survival, ORR Overall Response Rate, RGX-104 LXR inhibitor, MTD Maximum Tolerated Dose, INCB059872 LSD1 inhibitor, AEs Adverse Events, Rova-T Rovalpituzumab Tesirine, DLT Dose limiting toxicities, INCAGN01876 anti-GITR antibody, INCAGN01949 anti-OX40 antibody, SGI-110 DNMT inhibitor, Trilaciclib CDK4/6 inhibitor, Utomilumab anti-CD137 antibody